Compare GOCO & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | INTS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 19.2M |
| IPO Year | 2020 | 2021 |
| Metric | GOCO | INTS |
|---|---|---|
| Price | $1.14 | $5.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.75 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 53.5K | 25.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $361,845,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.19 |
| 52 Week High | $10.56 | $8.06 |
| Indicator | GOCO | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 42.45 |
| Support Level | $1.00 | $5.04 |
| Resistance Level | $1.35 | $8.06 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 49.28 | 25.33 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions, so it can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. The proprietary technology platform integrates artificial intelligence and modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.